{"contentid": 487924, "importid": NaN, "name": "WuXi AppTec buys UK CRDO firm for $135 million", "introduction": "China\u00e2\u0080\u0099s WuXi AppTec (SHA: 603259) yesterday announced the completion of a $135 million acquisition of OXGENE, a pioneering UK-based contract research and development organization that designs and develops scalable gene therapy technologies.", "content": "<p>China&rsquo;s WuXi AppTec (SHA: 603259) yesterday announced the completion of a $135 million acquisition of OXGENE, a pioneering UK-based contract research and development organization that designs and develops scalable gene therapy technologies.&nbsp;</p>\n<p>This deal broadens Wuxi&rsquo;s customer offerings, allowing them to provide&nbsp;end-to-end support in the creation of cutting-edge cell and gene therapies, from early genetic molecular research and discovery through development and cGMP manufacturing at scale for global commercialization.&nbsp;</p>\n<p>The importance of this acquisition is the potential for faster, less expensive, and more accurate commercialization at scale of cell and gene therapies for patients worldwide. These changes have the potential to improve commercialization of advanced molecular therapies by multiple orders of magnitude, says WuXi AppTec, a provider of R&amp;D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries.</p>\n<p>OXGENE&rsquo;s novel TESSA technology for adeno-associated viral (AAV) manufacturing and XLenti stable solutions for lentiviral manufacturing simplify cell and gene therapy manufacturing&nbsp;while significantly reducing costs.&nbsp;</p>", "date": "2021-03-03 10:03:00", "meta_title": "WuXi AppTec buys UK CRDO firm for $135 million", "meta_keywords": "WuXi AppTec, OXGENE, Acquisition, M&A, CRDO", "meta_description": "WuXi AppTec buys UK CRDO firm for $135 million", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-03 09:11:07", "updated": "2021-03-03 10:03:26", "access": NaN, "url": "https://www.thepharmaletter.com/article/wuxi-apptec-buys-uk-crdo-firm-for-135-million", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "wuxi-chanzhou-big.jpg", "image2id": "wuxi-chanzhou-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": NaN, "topic_tag": "Companies, mergers and acquisitions, Outsourcing, CRO and CMO", "geography_tag": "China, UK", "company_tag": "OXGENE, UK CRDO, WuXi Apptec", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-03 10:03:00"}